|
May 06, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
May 05, 2022
|
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
|
|
|
May 04, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Apr 27, 2022
|
European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva
|
|
|
Apr 21, 2022
|
BioCryst to Report First Quarter 2022 Financial Results on May 5
|
|
|
Apr 11, 2022
|
BioCryst to Present at Upcoming Investor Conference
|
|
|
Apr 08, 2022
|
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
|
|
|
Apr 05, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Mar 03, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Mar 02, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
